In 2025, the Center for Biologics Evaluation and Research (CBER) approved a series of groundbreaking biological products and devices, each contributing to advancements in healthcare and patient safety. Below is an overview of notable approvals and regulatory developments during this period.
Biological License Application (BLA) Approvals
Automated C3d Plate (Anti-Human Globulin, Murine Monoclonal)
- Indication for Use: Designed for use on Echo Lumena and Galileo Echo systems, this product facilitates automated direct antiglobulin tests (DAT) requiring C3d detection.
- Manufacturer: Immucor, Inc., Norcross, GA.
- Approval Date: January 8, 2025.
Noteworthy BLA Supplement Approvals
Anti-Human Globulin
- Purpose: This supplement replaces the Anti-C3d component in MTS Anti-IgG, -C3d gel cards produced at the Pompano Beach, Florida facility.
- Manufacturer: Micro Typing Systems, Inc., Rochester, NY.
- Approval Date: January 28, 2025.
Biological Device Application Approvals
Adaptive Nomogram Bottle
- Description: An empty container intended to collect and process blood and its components.
- Indication: Used for the collection, storage, and shipment of plasma before fractionation.
- Manufacturer: Fresenius Kabi AG, Lake Zurich, IL.
- Clearance Date: February 21, 2025.
Lookback Notification System Version 2.0
- Description: A blood establishment computer software designed to generate and maintain electronic lookback records.
- Indication: Facilitates automated creation, distribution, and updating of consignee notifications to effectively identify and remove unsuitable Source Plasma units before manufacturing.
- Manufacturer: BioLife Plasma Services LP, Bannockburn, IL.
- Clearance Date: February 20, 2025.
Aurora Xi Plasmapheresis System Software Version 2.0
- Description: An automated blood cell separator.
- Indication: Intended for the automated collection of plasma via membrane filtration to be processed as Source Plasma.
Regulatory Developments and Guidance
In 2025, the FDA’s Center for Biologics Evaluation and Research (CBER) released its guidance agenda, highlighting several key focus areas:
- Blood and Blood Components: Five documents were listed, including a new draft guidance on evaluating the use of non-D1(2-ethylhexyl) phthalate (non-DEHP) materials.
- Therapeutic Products: Fourteen guidances were planned, with topics such as platform technologies in gene therapy products incorporating genome editing and post-approval methods to capture safety and efficacy data.
- Other Areas: Guidances on standardized formats for electronic submissions and recommendations for validating alternative microbial methods for biologics testing were also included.
Industry Trends and Compliance Focus
Manufacturers were advised to prepare for several regulatory changes anticipated in 2025:
- FDA Rule on Laboratory Developed Tests (LDTs): By May 6, 2025, laboratories with LDTs were required to have processes in place for complaint evaluation, Medical Device Reporting (MDR), and recalls.
- EU In Vitro Diagnostic Regulation (IVDR): Full compliance for In Vitro Diagnostic (IVD) manufacturers was mandated by May 26, 2025. This included implementing Quality Management Systems (QMS) per ISO 13485 standards.
Conclusion
The year 2025 marked significant advancements in the approval and regulation of biological products and medical devices. CBER’s approvals underscored a commitment to enhancing public health through innovative solutions, while regulatory developments emphasized the importance of compliance and quality in the evolving healthcare landscape.
At Atlas, you will get the latest information related to biological approvals, regulatory updates, and industry insights. Schedule a demo today to discover how Atlas can support your compliance and research needs.